Claims

This listing of claims will replace all prior listings of claims:

Claim 1 (Currently amended): A method of inhibiting endothelial cell growth in a subject in need of inhibiting endothelial cell growth, comprising:

contacting an endothelial cell in the subject with a polypeptide comprising an amino acid sequence at least ~~90%~~ 95% homologous to an amino acid sequence as set forth in SEQ ID NO: 2, or a therapeutically effective fragment thereof, wherein the polypeptide, or therapeutically effective fragment thereof, inhibits endothelial cell growth in the subject.

~~thereby inhibiting endothelial cell growth~~.

Claim 2 (Withdrawn): The method of claim 1, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 6.

Claim 3 (Withdrawn): The method of claim 1, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 8.

Claim 4 (Withdrawn): The method of claim 1, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 5.

Claim 5 (Currently amended): A method of inhibiting angiogenesis in a subject in need of anti-angiogenic therapy, comprising:

administering to the subject a composition comprising a polypeptide comprising an amino acid sequence at least ~~90%~~95% homologous to an amino acid sequence as set forth in SEQ ID NO: 2, or a therapeutically effective fragment thereof, wherein the polypeptide, or therapeutically effective fragment thereof, inhibits angiogenesis in the subject.

~~thereby inhibiting angiogenesis in the subject~~.

Claim 6 (Previously presented): The method of claim 5, wherein the composition further comprises a pharmaceutically acceptable carrier.

Claim 7 (Withdrawn): The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 6.

Claim 8 (Withdrawn): The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 8.

Claims 9-12 (Canceled).

Claim 13 (Previously presented): The method of claim 5, further comprising administering an anti-angiogenic agent comprising platelet-factor-4, IP-10 (interferon (IFN)-γ inducible protein-10), MIG (Monokine induced by IFN-γ), INF-γ, IFN-α, angiostatin, endostatin, fumagillin, AGM-1470, thrombospondin, a fragment of prolactin, antibody against the integrin $\alpha_v\beta_3$, IL-12, cleaved conformation of the serpin antithrombin, thalidomide, or a mixture thereof.

Claim 14 (Previously presented): The method of claim 5, further comprising administering a chemotherapeutic agent.

Claim 15 (Previously presented): The method of claim 5, further comprising administering a hormone.

Claim 16 (Previously presented): The method of claim 5, further comprising administering an anti-inflammatory agent.

Claim 17 (Previously presented): The method of claim 5, further comprising administering an anti-viral agent.

Claim 18-19 (Canceled).

Claim 20 (Previously presented): The method of claim 5, wherein the subject has periodontal disease.

Claim 21 (Previously presented): The method of claim 20, further comprising administering an antibiotic.

Claim 22 (Previously presented): The method of claim 5, wherein the subject has a radiation induced injury.

Claim 23 (Previously presented): The method of claim 5, wherein the subject has a chemotherapy induced injury.

Claim 24 (Previously presented): The method of claim 5, wherein the composition inhibits angiogenesis, wherein angiogenesis is stimulated in the subject by an angiogenesis inducer comprising basic fibroblast growth factor, acidic fibroblast growth factor, Vascular Endothelial Growth Factor (VEGF), hepatocyte growth factor, Interleukin (IL)-15, IL-8, platelet-derived endothelial cell growth factor (PDECGF), Transforming Growth Factor (TGF)-β, Tumor necrosis Factor (TNF)α, angiogenin, cripto, or a mixture thereof.

Claim 25 (Original): The method of claim 5, wherein the subject is immunocompromized due to T-lymphocyte deficiency.

Claims 26-56 (Canceled).

Claim 57 (Previously presented): The method of claim 1, wherein the therapeutically effective fragment of calreticulin consists essentially of:

(a) an amino acid sequence as set forth in SEQ ID NO: 5;

(b) an amino acid sequence as set forth in SEQ ID NO: 6;

(c) an amino acid sequence as set forth in SEQ ID NO: 8;

(d) an amino acid sequence as set forth in SEQ ID NO: 9; or

(e) an amino acid sequence as set forth in SEQ ID NO: 4.

Claims 58-59 (Canceled).

Claim 60 (Previously presented): The method of claim 1, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 4.

Claim 61 (Withdrawn): The method of claim 1, wherein the therapeutically effective fragment comprises SEQ ID NO: 9.

Claim 62 (Canceled).

Claim 63 (Previously presented): The method of claim 62, wherein the polypeptide comprises an amino acid sequence at least 98% homologous to an amino acid sequence as set forth in SEQ ID NO: 2.

Claim 64 (Previously presented): The method of claim 63, wherein the polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 2.

Claim 65 (Withdrawn): The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 5.

Claim 66 (Previously presented): The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 4.

Claim 67 (Withdrawn): The method of claim 5, wherein the therapeutically effective fragment comprises an amino acid sequence as set forth in SEQ ID NO: 9.

Claim 68 (Canceled).

Claim 69 (Previously presented): The method of claim 68, wherein the polypeptide comprises an amino acid sequence at least 98% homologous to an amino acid sequence as set forth in SEQ ID NO: 2.

Claim 70 (Previously presented): The method of claim 69, wherein the polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 2.

Claims 71-76 (Canceled).

Claim 77 (Previously presented): The method of claim 5, wherein the subject has Kaposi sarcoma.

Claim 78 (Previously presented): The method of claim 1, wherein the endothelial cell is *in vitro*.

Claim 79 (Previously presented): The method of claim 1, wherein the endothelial cell is *in vivo*.

Claim 80 (Previously presented): The method of claim 1, wherein the endothelial cell is in a tumor in a subject.

Claim 81 (Previously presented): The method of claim 5, wherein the subject has a tumor.